M.L. Shiffman

Sofosbuvir/Velpatasvir in Combination with Ribavirin for 24 Weeks is Effective Retreatment for Patients who failed Prior NS5A Containing DAA Regimens: Results of the GS-US-342-1553 Study

Edward Gane, M.L. Shiffman, K. Peter Etzkorn et al. · Journal of Hepatology · 2016 · 32 citations

Medicine, Pharmacology, Pharmacotherapy +16

734 Peginterferon alpha-2a (PEGASYS) plus ribavirin (COPEGUS) for 16 or 24 weeks in patients with HCV genotype 2 OR 3. Final results of the accelerate trial

M.L. Shiffman, S. Chris Pappas, Lisa M. Nyberg et al. · Journal of Hepatology · 2006 · 28 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +15

1177 RAPID AND SUSTAINED ACHIEVEMENT OF UNDETECTABLE HCV RNA DURING TREATMENT WITH RITONAVIR-BOOSTED DANOPREVIR/PEG-IFNa-2A/RBV IN HCV GENOTYPE 1 OR 4 PATIENTS: DAUPHINE WEEK 12 INTERIM ANALYSIS

Greg Everson, C. Cooper, Christophe Hézode et al. · Journal of Hepatology · 2012 · 18 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +13

SOF/VEL/VOX for 8 or 12 weeks is well tolerated and results in high SVR12 rates in patients receiving opioid substitution therapy

Jason Grebely, Ira M. Jacobson, Zeid Kayali et al. · Journal of Hepatology · 2017 · 18 citations

Medicine, Pharmacology, Pharmacotherapy +3

4 SVR WITH TELAPREVIR, PEGINTERFERON ALFA-2A AND RIBAVIRIN IN HCV PATIENTS WITH WELL-CHARACTERIZED PRIOR NULL RESPONSE, PARTIAL RESPONSE, VIRAL BREAKTHROUGH OR RELAPSE AFTER PR

Thomas Berg, John G. McHutchison, Nathalie Adda et al. · Journal of Hepatology · 2010 · 17 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +14